Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference
Generation Bio (Nasdaq: GBIO), a biotechnology company focused on developing treatments for T cell-driven autoimmune diseases, has announced its participation in the upcoming TD Cowen 45th Annual Health Care Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Generation Bio (Nasdaq: GBIO), a biotechnology company focused on developing treatments for T cell-driven autoimmune diseases, has announced its participation in the upcoming TD Cowen 45th Annual Health Care Conference.
The company's president and CEO, Geoff McDonough, M.D., will deliver a presentation on Monday, March 3, 2025, at 9:10 a.m. ET in Boston. Investors and interested parties can access a live webcast of the presentation through the investor section of Generation Bio's website at investors.generationbio.com. The presentation recording will remain available for replay on the website for 30 days after the event.
Details
News Market Reaction – GBIO
The recorded move for GBIO in the trading session of this news was -1.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is a biotechnology company changing what's possible for people living with T cell-driven autoimmune diseases. The company is developing a new modality of therapeutics leveraging its T cell-selective cell-targeted lipid nanoparticle (ctLNP) to deliver siRNA in vivo, enabling modulation of T cell activity that causes inflammation and auto-reactive tissue destruction. By selectively modulating T cells that drive disease pathology, ctLNP-siRNA therapeutics could potently block target function with sequence-level specificity while sparing the broader immune system. This potent new modality is designed to reach targets that are poorly drugged by other approaches, opening a broad indication space of T cell-driven autoimmune diseases.
For more information, please visit www.generationbio.com.
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.